Fig. 2. Western blots of proteinase K (PK)-treated brain homogenates from transgenic mice, human cases of variant and sporadic CJD, and lines of wild-type mice. (A) Lane 1, vCJD; lane 2, vCJD-inoculated 129MM Tg35 mouse. (B) Lane 1, vCJD-inoculated 129MM Tg35 mouse; lane 2, BSE-inoculated 129MM Tg35 mouse propagating type 2 PrPSc; lane 3, vCJD. (C) Lanes 1 and 2, BSE-inoculated 129MM Tg35 mouse propagating either type 2 PrPSc (lane 1) or type 4 PrPSc (lane 2). (D) Lane 1, BSE-inoculated 129MM Tg35 mouse propagating type 2 PrPSc; lane 2, human sporadic CJD type 2 PrPSc (PRNP genotype 129MM). (E) Lanes 1–3, human sporadic CJD type 2 PrPSc (PRNP genotype 129MM); lanes 4–6, BSE-inoculated 129MM Tg35 mouse propagating type 2 PrPSc. Samples were PK digested in the absence (lanes 1, 3, 4 and 6) or presence (lanes 2 and 5) of 25 mM EDTA. *Following proteolysis, samples in lanes 3 and 6 were boiled in SDS sample buffer and subsequently adjusted to 25 mM EDTA before electrophoresis. (F) Transmission of vCJD and BSE to 129MM Tg45 mice. Lane 1, vCJD; lane 2, vCJD-inoculated 129MM Tg45 mouse; lane 3, BSE- inoculated 129MM Tg45 mouse. (G) Primary transmission of vCJD and BSE to wild-type inbred mice. Lane 1, BSE-inoculated FVB mouse; lane 2, vCJD-inoculated FVB mouse; lane 3, BSE-inoculated C57BL/6 mouse; lane 4, BSE-inoculated SJL mouse; lane 5, vCJD-inoculated SJL mouse; lane 6, BSE-inoculated RIIIS mouse. (H) Secondary transmission of vCJD and BSE in wild-type inbred mice. Lanes 1–4, BSE was passaged twice in C57BL/6 mice and then passaged in different wild-type mice: lane 1, C57BL/6 mouse; lane 2, FVB mouse; lane 3, SJL mouse; lane 4, RIIIS mouse. Lanes 5 and 6, second passage of SJL-passaged BSE in further SJL mice (lane 5) or FVB mice (lane 6). Western blots were analysed by high-sensitivity ECL using biotinylated anti-PrP monoclonal antibody ICSM 35 (A–D, F–H) or 3F4 (E).